Eli Lilly and Innovent Biologics partner on the distribution and promotion of Jaypirca in China, the first non-covalent BTK ...

Inify Laboratories raises $12.3 million through private placement to support UK expansion and AI-driven prostate cancer ...

Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned ...

Japan’s largest drugmaker, Takeda Pharmaceuticals, announced it is working with the European Medicines Agency (EMA) to ...

RemeGen’s Phase III trial of disitamab vedotin shows improved progression-free survival in advanced breast cancer patients ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...

The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% ...

Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday.

Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to ...

UK-based Puretech Health has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at ...

BioNTech resumes its PRESERVE-003 trial for gotistobart as a monotherapy in metastatic squamous NSCLC after a partial ...

VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...